186 related articles for article (PubMed ID: 27211612)
21. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
22. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
[TBL] [Abstract][Full Text] [Related]
24. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
[TBL] [Abstract][Full Text] [Related]
25. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
[TBL] [Abstract][Full Text] [Related]
26. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
28. A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.
Shapiro EG; Nestrasil I; Delaney KA; Rudser K; Kovac V; Nair N; Richard CW; Haslett P; Whitley CB
J Pediatr; 2016 Mar; 170():278-87.e1-4. PubMed ID: 26787381
[TBL] [Abstract][Full Text] [Related]
29. Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation.
Kresse H; Paschke E; von Figura K; Gilberg W; Fuchs W
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6822-6. PubMed ID: 6450420
[TBL] [Abstract][Full Text] [Related]
30. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
Perkins KJ; Muller V; Weber B; Hopwood JJ
Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
[TBL] [Abstract][Full Text] [Related]
31. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)].
Zhang WM; Shi HP; Meng Y; Li BT; Qiu ZQ; Liu JT
Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):407-10. PubMed ID: 19099774
[TBL] [Abstract][Full Text] [Related]
32. Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B.
Whitley CB; Cleary M; Eugen Mengel K; Harmatz P; Shapiro E; Nestrasil I; Haslett P; Whiteman D; Alexanderian D
J Pediatr; 2018 Jun; 197():198-206.e2. PubMed ID: 29661560
[TBL] [Abstract][Full Text] [Related]
33. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice.
Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD
Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018
[TBL] [Abstract][Full Text] [Related]
34. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK
J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of biomarkers for Sanfilippo syndrome.
Saville JT; Flanigan KM; Truxal KV; McBride KL; Fuller M
Mol Genet Metab; 2019; 128(1-2):68-74. PubMed ID: 31104888
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B.
Muschol N; Koehn A; von Cossel K; Okur I; Ezgu F; Harmatz P; de Castro Lopez MJ; Couce ML; Lin SP; Batzios S; Cleary M; Solano M; Nestrasil I; Kaufman B; Shaywitz AJ; Maricich SM; Kuca B; Kovalchin J; Zanelli E
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413418
[TBL] [Abstract][Full Text] [Related]
38. Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase.
Mok A; Cao H; Hegele RA
Genomics; 2003 Jan; 81(1):1-5. PubMed ID: 12573255
[TBL] [Abstract][Full Text] [Related]
39. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
[TBL] [Abstract][Full Text] [Related]
40. Clinical heterogeneity in Sanfilippo disease (mucopolysaccharidosis III) type D: presentation of two new cases.
Coppa GV; Giorgi PL; Felici L; Gabrielli O; Donti E; Bernasconi S; Kresse H; Paschke E; Mastropaolo C
Eur J Pediatr; 1983 Apr; 140(2):130-3. PubMed ID: 6411475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
